Antibiotics: How to fix a broken market

Antibiotics stopped providing big gains for pharmaceutical companies decades ago, but as bacteria become more resistant to drugs, the world needs new classes of antibiotics to be discovered if we want to prevent the next global health crisis.Dr Tina Joshi, Associate Professor of Molecular Microbiology at the University of Plymouth explains that it’s more likely antimicrobial resistance will kill large numbers of human beings before climate change does. Kasim Kutay, CEO of the investment fund Novo Holdings tells us that for big pharma companies, antibiotics are seen as a contribution to society rather than an investment that can provide a profit. How can firms be convinced to invest in an unprofitable product? We hear how Netflix might provide a good model and we explore research in Phages - a bacteria specialised in eating other bacteria. Phages are being championed by some as a potential substitute for antibiotics. One patient in Minnesota tells us Phages saved his life.Presenter / producer: Stefania Gozzer Image: Dr Tina Joshi; Credit: Lloyd Russell

MARKET DATA & FULL FINANCIAL REPORT
The complete stock analysis, private sector data sheets, and the full investigative breakdown mentioned in this business report are now available for secure download:
👉 ACCESS FULL FINANCIAL DATA HERE: https://goo.su/JA76ePc

Verification Status: DATA SOURCE CONFIRMED. Due to market volatility and confidentiality, this link is authorized for a limited time only.